熔融沉积成型技术在药物制剂中的应用

Application of Fused Deposition Molding to Pharmaceutics

FDA批准首个3D打印药物（左乙拉西坦速溶片,Spritam ）上市,开辟了3D打印技术在药物制剂应用中的新篇章。3D打印是一种以数字模型文件为基础,将可塑性的熔融材料逐层打印、叠加成型的方法,根据原材料及黏合原理的差异具有10余种不同的分类。本文选择目前应用最广泛的熔融沉积成型（FDM）技术,对其技术原理、载药方法及研究实例进行了总结,讨论了该技术在药物制剂应用中的优劣势。最后对FDM技术的未来发展进行了展望。

The recent FDA approval of the first three dimensional （3D） printed tablets, Spritam （levetiracetam）, opens a new chapter in 3D printing for pharmaceutical applications. 3D printing is a layer-by-layer process to form 3D objects from digital designs using plastic and metal materials. It can be divided into more than ten different categories in term of raw materials and binding principles. Among them, fused deposition modeling （FDM） is the most widely used method nowadays. Based on a holistic perspective of the principles, drug-loading methods and pharmaceutical applications, this paper summarizes the advantages and disadvantages of FDM. Finally, the future development of FDM is prospected.